David Duggan

David Duggan Ph.D.

Associate Professor


Technical Advisor
Office of Chief Operating Officer

Former-Head
Population Genetics Lab

David Duggan Ph.D.

David Duggan, Ph.D., is a leading scientist and market/technical analyst with 25 years of scientific expertise and nearly a decade of experience advising equity management firms on many of the leading genomics and personalized medicine companies. As a scientist, he served as Director, Population Genetics Laboratory, Director, High Throughput Genotyping Technology Center, and Associate Professor, Genetic Basis of Human Disease Division, Translational Genomics Research Institute (TGen). He also holds an adjunct faculty appointment with the Mayo Clinic in the Genetic Epidemiology and Risk Assessment Division. 

Dr. Duggan has managed both a research laboratory and industry contracts. During the most recent 10 years, he has collaborated on many research grants generating greater than $35M in revenue. His responsibilities have included evaluating the utility, cost-benefit and practical application of existing and new technologies; negotiating research partnerships specializing in scientific and business strategies involving national and international consortia. He has published more than 140 peer-reviewed manuscripts; 6 invited reviews; 3 book chapters; and, co-edited a book. Research in his laboratory focused on the use personalized medicine approaches to identify the genetic basis of disease (diagnosis), prognosis, or therapeutic course; his laboratory has generated genetic/genomic data on >300,000 samples. 

Dr. Duggan is a member of the steering committees for several National Institutes of Health funded consortiums; an invited participant in several national and international scientific review panels; and, has been an invited participant in the scientific advisory committees for two leading genomic technology companies.

As a technology and applications expert in the field of genomics and personalized medicine, he has provided consultation services to dozens of equity management firms where he provided market analysis for genomics and personalized medicine companies—many of whom have enjoyed year-over-year revenue growth rates of 25-30% year after year during the period of time Dr. Duggan had been working with market analysts.  He achieved a top 5% requested consultant ranking with a leading New York consulting firm. Dr. Duggan provided detailed market overviews (past, present, future) on product volume, revenue, growth, industry trends (1, 3, and 5 year forecasts) and technical analyses including general education of clients, detailed individual product review, detailed product review for a single company, detailed product comparison and contrast within and between companies and detailed company comparisons. Dr. Duggan fulfilled consultant requests pertaining to many of the industry leading genomics and personalized medicine companies in business today. 

Dr. Duggan received his Ph.D. in human genetics from the University of Pittsburgh and obtained his post-doctoral training in genomics at the National Human Genome Research Institute, National Institutes of Health (Bethesda, MD). 


Selected Publications

Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study. Robson ME, Reiner AS, Brooks JD, Concannon PJ, John EM, Mellemkjaer L, Bernstein L, Malone KE, Knight JA, Lynch CF, Woods M, Liang X, Haile RW, Duggan DJ, Shore RE, Smith SA, Thomas DC, Stram DO, Bernstein JL; WECARE Study Collaborative Group. J Natl Cancer Inst. 2017; 109.

Genome-wide association study of colorectal cancer identifies six new susceptibility loci. Schumacher FR, Schmit SL, Jiao S, Edlund CK, .. Duggan D, .. Gruber SB, Peters U. Nat Commun. 2015; 6: 7138.

Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Helfand BT, Roehl KA, Cooper PR, McGuire BB,.. Duggan D,.. Taylor JA, Catalona WJ. Hum Genet. 2015; 134: 439-50.

The identification of trans-associations between prostate cancer GWAS SNPs and RNA expression differences in tumor-adjacent stroma. Chen X, McClelland M, Jia Z, Rahmatpanah FB, Sawyers A, Trent J, Duggan D, Mercola D. Oncotarget. 2015 Jan 30; 6: 1865-73.

Fine-Mapping IGF1 and Prostate Cancer Risk in African Americans: The Multiethnic Cohort Study. Giorgi EE, Stram DO, Taverna D, Turner SD, Schumacher F, Haiman CA, Lum-Jones A, Tirikainen M, Caberto C, Duggan D, Henderson BE, Le Marchand L, Cheng I. Cancer Epidemiol Biomarkers Prev. 2014; 23: 1928-32.

Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk. Zhang B, Jia WH, Matsuda K, Kweon SS,.. Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO)*,.. Colon Cancer Family Registry (CCFR)*,.. Zeng YX, Zheng W. Nat Genet. 2014 Jun;46(6):533-42. doi: 10.1038/ng.2985. Epub 2014 May 18.

A Genome-wide Association Study of Early-onset Breast Cancer Identifies PFKM as a Novel Breast Cancer Gene and Supports a Common Genetic Spectrum for Breast Cancer at Any Age. Ahsan H, Halpern J, Kibriya MG, Pierce BL,.. Duggan D,.. Cox NJ, Whittermore AS. Cancer Epidemiol Biomarkers Prev. 2014 Feb 3. [Epub ahead of print]

Identification of Novel Variants in Colorectal Cancer Families by High-Throughput Exome Sequencing. Derycke MS, Gunawardena SR, Middha S, Asmann YA,.. Duggan D,.. Thibodeau SN, Goode EL. Cancer Epidemiol Biomarkers Prev. 2013 May 1. [Epub ahead of print]

Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. Wu Y, Waite LL, Jackson AU, Sheu WH,.. Duggan D,.. North KE, Mohlke KL. PLoS Genet. 2013 Mar. Epub 2013 Mar 21.

Loci influencing blood pressure identified using a cardiovascular gene-centric array. Ganesh SK, Tragante V, Guo W, Guo Y,.. Duggan D,.. Keating BJ, Asselbergs FW. Hum Mol Genet. 2013 Jan 8. [Epub ahead of print]

Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals. Guo Y, Lanktree MB, Taylor KC, Hakonsarson H, Lange LA, Keating BJ; The IBC 50K SNP array BMI Consortium. Hum Mol Genet. 2012 Oct 24. [Epub ahead of print].

Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH,.. Duggan D,.. Kiel DP, Rivadeneira F. Nat Genet. 2012; 44: 491-501.

Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals. Dunlop MG, Tenesa A, Farrington SM, Ballereau S,.. Duggan D,.. Tomlinson I, Houlston RS. Gut. 2012 May 22. [Epub ahead of print].

Evaluation of the Metabochip Genotyping Array in African Americans and Implications for Fine Mapping of GWAS-Identified Loci: The PAGE Study. Buyske S, Wu Y, Carty CL, Cheng I,.. Duggan D,.. Crawford DC, North KE. PLoS One. 2012; 7: e35651.

cis-Expression QTL analysis of established colorectal cancer risk variants in colon tumors and adjacent normal tissue. Loo LW, Cheng I, Tiirikainen M, Lum-Jones A, Seifried A, Dunklee LM, Church JM, Gryfe R, Weisenberger DJ, Haile RW, Gallinger S, Duggan DJ, Thibodeau SN, Casey G, Le Marchand L. PLoS One. 2012; 7: e30477.

Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallée MP, Tavtigian SV, Concannon P, Foulkes WD, Bernstein L., WECARE Study Collaborative Group, Bernstein JL, Begg CB. Hum Mutat. 2012; 33: 674-80.

Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses. Lu Y, Sun J, Kader AK, Kim ST, Kim JW, Liu W, Sun, J, Lu D, Feng J, Zhu Y, Jin T, Zhang Z, Dimitrov L, Lowey J, Campbell K, Suh E, Duggan D, Carpten J, Trent JM, Gronberg H, Zheng SL, Isaacs WB, Xu J. Prostate. 2011 Jun 10.

Principles for the post-GWAS functional characterization of cancer risk loci. Freedman ML, Monteiro AN, Gayther SA, Coetzee GA, Risch A, Plass C, Casey G, De Biasi M, Carlson C, Duggan D, James M, Liu P, Tichelaar JW, Vikis HG, You M, Mills IG. Nat Genet. 2011; 43: 513-8.

Fine-mapping of colorectal cancer susceptibility loci at 8q23.3, 16q22.1 and 19q13.11: refinement of association signals and use of in silico analysis to suggest functional variation and unexpected candidate target genes. Carvajal-Carmona LG, Cazier JB, Jones AM, Howarth K, Broderick P, Pittman A, Dobbins S, Tenesa A, Farrington S, Prendergast, J, Theodoratou E, Barnetson R, Conti D, Newcomb P, Hopper JL, Jenkins MA, Gallinger S, Duggan DJ, Campbell H, Kerr D, Casey G, Houlston R, Dunlop M, Tomlinson I. Hum Mol Genet. 2011 May 22. [Epub ahead of print]

Genome-wide copy number variations analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer. Jin G, Sun J, Liu W, Zhang Z, Chu LW, Kim ST, Sun J, Feng J, Duggan D, Carpten JD, Wiklund F, Grönberg H, Isaacs WB, Zheng SL, Xu J. Carcinogenesis. 2011 May 5. [Epub ahead of print]

Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Xu J, Zheng SL, Isaacs SD, Wiley KE, Wiklund F, Sun J, Kader AK, Li G, Purcell LD, Kim ST, Hsu FC, Stattin P, Hugosson J, Adolfsson J, Walsh PC, Trent JM, Duggan D, Carpten J, Grönberg H, Isaacs WB. Proc Natl Acad Sci U S A. 2010; 107: 2136-40.

Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Zheng SL, Sun J, Wiklund F, Gao Z, Stattin P, Purcell LD, Adami HO, Hsu FC, Zhu Y, Adolfsson J, Johansson JE, Turner AR, Adams TS, Liu W, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Grönberg H. Clin Cancer Res. 2009; 15: 1105-11.

Cumulative association of five genetic variants with prostate cancer. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami H-O, Hsu F-C, Zhu Y, Balter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang B-L, Isaacs WB, Xu J, Gronberg H. N. Engl. J. Med. 2008; 358: 910-919.

A search for variants associated with young-onset Type 2 Diabetes in American Indians among 80,044 single nucleotide polymorphisms. Hanson RL, Bogardus C, Duggan D, Kobes S, Knowlton M, Infante AM, Marovich L, Benitez D, Baier LJ, Knowler WC. Diabetes 2007; 56: 3045-3052.

Human Prostate Cancer and Benign Prostatic Hyperplasia: Molecular Dissection by Gene Expression Profiling. Luo J*, Duggan DJ*, Chen Y, Sauvageot J, Ewing C, Bittner M, Trent JM, Isaacs WB. Cancer Research 2001; 61: 4683-4688.

Gene expression profiles in hereditary breast cancer. Hedenfalk I*, Duggan D*, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi O, Wilfond B, Borg A, Trent J. N. Engl. J. Med. 2001; 344: 539-48.

Mutations in the -sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2). Duggan DJ, Manchester D, Stears KP, Mathews DJ, Hart C, Hoffman EP. Neurogenetics 1997; 1: 49-58.

Mutations in the sarcoglycan genes in patients with myopathy. Duggan DJ, Gorospe JR, Fanin M, Hoffman EP, Angelini C. N. Engl. J. Med. 1997; 336: 618-624.

Mutations that disrupt the carboxyl-terminus of -sarcoglycan cause muscular dystrophy. McNally E*, Duggan D*, Gorospe JR, Bönnemann C, Fanin M, Pegoraro E, Lidov HGW, Noguchi S, Ozawa E, Finkel RS, Cruse RP, Angelini C, Kunkel LM, Hoffman EP. Hum. Mol. Genet. 1996; 5: 1841-1847.

A microsatellite-based multipoint index map of human chromosome 22. Buetow KH, Duggan D, Yang B, Ludwigsen S, Puck J, Porter J, Budarf M, Spielman R, Emanuel BS. Genomics 1993; 18: 329-339.
Back To Top